慢性肾脏病(chronic kidney disease，CKD)全球患病率高，社会负担重，其常见并发症高钾血症是一种可危及生命的电解质紊乱，与患者全因和心血管死亡率升高显著相关。同时，CKD合并心血管疾病需要使用肾素-血管紧张素-醛固酮系统拮抗剂(renin-angiotensin-aldosterone system inhibitor，RAASi)，可加重高钾血症风险，并转而限制RAASi在该人群中的应用。因此，使用合理的钾结合剂对改善CKD患者整体预后和减轻患者经济负担具有重大意义。本综述旨在对Patiromer和环硅酸锆钠(sodium zirconium cyclosilicate，SZC)在CKD患者中应用的研究进行归纳和总结，以期对后续研究开展提供参考。
Chronic kidney disease (CKD) is a worldwide disease with higher prevalence, and makes a tremendous burden to the societies. Hyperkalemia is a common and life-threatening electrolyte imbalance complication, and is closely related to the higher all-cause and cardiovascular mortality of this disease. Meanwhile, the use of renin-angiotensin-aldosterone system inhibitor (RAASi) in CKD patients with cardiovascular disease aggravates the risk of hyperkalemia, which may limit the use of RAASi in this particular population. Therefore, appropriate use of potassium-binding agents is of great significance to improve the overall prognosis and to relieve their economic burden. This review aims to summarize the application of patiromer and sodium zirconium cyclosilicate (SZC) in CKD patients in order to provide references for further studies.
[1] Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. The Lancet, 2020, 395(10225): 709-33.
[2] Nakhoul GN, Huang H, Arrigain S, et al. Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease[J]. Am J Nephrol, 2015, 41(6): 456-63.
[3] Luo J, Brunelli SM, Jensen DE, et al. Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function[J]. Clin J Am Soc Nephrol, 2016, 11(1): 90-100.
[4] Valdivielso JM, Balafa O, Ekart R, et al. Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies[J]. Drugs, 2021, 81(13): 1467-89.
[5] Xu X, Li Z, Chen Y, et al. Dietary fibre and mortality risk in patients on peritoneal dialysis[J]. Br J Nutr, 2019, 122(9): 996-1005.
[6] Noel JA, Bota SE, Petrcich W, et al. Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age[J]. JAMA Intern Med, 2019, 179(8): 1025-33.
[7] Drugs@FDA: FDA-Approved Drugs-Lokelma. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207078s007lbl.pdf.
[8] Drugs@FDA: FDA-Approved Drugs-Veltassa. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/205739s035lbl.pdf.
[9] Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors[J]. N Engl J Med, 2015, 372(3): 211-21.
[10] Bakris GL, Pitt B, Weir MR, et al. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial[J]. JAMA, 2015, 314(2): 151-61.
[11] Bushinsky DA, Williams GH, Pitt B, et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia[J]. Kidney Int, 2015, 88(6): 1427-33.
[12] Bushinsky DA, Rossignol P, Spiegel DM, et al. Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis[J]. Am J Nephrol, 2016, 44(5): 404-10.
[13] Rafique Z, Liu M, Staggers KA, et al. Patiromer for Treatment of Hyperkalemia in the Emergency Department: A Pilot Study[J]. Acad Emerg Med, 2020, 27(1): 54-60.
[14] Ash SR, Singh B, Lavin PT, et al. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient[J]. Kidney Int, 2015, 88(2): 404-11.
[15] Fishbane S, Ford M, Fukagawa M, et al. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia[J]. J Am Soc Nephrol, 2019, 30(9): 1723-33.
[16] Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial[J]. Eur Heart J, 2011, 32(7): 820-8.
[17] Pitt B, Bushinsky DA, Kitzman DW, et al. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease[J]. ESC Heart Fail, 2018, 5(3): 257-66.
[18] Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial[J]. The Lancet, 2019, 394(10208): 1540-50.
[19] Dong J, Li YJ, Lu XH, et al. Correlations of lean body mass with nutritional indicators and mortality in patients on peritoneal dialysis[J]. Kidney Int, 2008, 73(3): 334-40.
[20] Xu X, Yang Z, Ma T, et al. The cut-off values of handgrip strength and lean mass index for sarcopenia among patients on peritoneal dialysis[J]. Nutr Metab (Lond), 2020, 17: 84.
